The popularity of Sildenafil initially fueled a surge for major pharmaceutical companies, nevertheless recent shifts present a murky scenario for investors. Generic versions are reducing revenue, and ongoing patent https://hamzahnwpe698712.affiliatblogger.com/93574053/the-blue-pill-and-pharma-a-volatile-bet